CBT
EBS icon

Capital Bank & Trust’s Emergent Biosolutions EBS Stock Holding History

Capital Bank & Trust’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-97
Closed -$5K – 692
2019
Q1 		$5K Buy
+97
New +$5.72K ﹤0.01% 593

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Capital Bank & Trust's EBS Position: Q2 2019 in Review

Capital Bank & Trust sold out of Emergent Biosolutions (EBS) in Q2 2019, closing a stake of 97 shares — an estimated $5K sold.

Capital Bank & Trust first reported a position in EBS in Q1 2019 and held it in 1 quarter. The position peaked at $5K in Q1 2019. 233 funds tracked by Wall St. Rank hold EBS as of Q2 2019.

  • Capital Bank & Trust reported no remaining Emergent Biosolutions position as of Q2 2019 after selling out during the quarter.
  • Capital Bank & Trust sold 97 Emergent Biosolutions shares in Q2 2019, an estimated $5K.
  • Capital Bank & Trust first reported a position in Emergent Biosolutions in Q1 2019 and held it in 1 quarter.
  • Capital Bank & Trust's Emergent Biosolutions position peaked at $5K in Q1 2019.
  • 233 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2019.

Based on Capital Bank & Trust's 13F filing for Q2 2019, filed 14 Aug 2019.